These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1001 related articles for article (PubMed ID: 28164848)
1. Gut Microbiota and Complications of Liver Disease. Acharya C; Bajaj JS Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848 [TBL] [Abstract][Full Text] [Related]
2. Alcoholic liver disease: the gut microbiome and liver cross talk. Hartmann P; Seebauer CT; Schnabl B Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593 [TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic Fatty Liver Disease and the Gut Microbiome. Boursier J; Diehl AM Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268 [TBL] [Abstract][Full Text] [Related]
4. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037 [TBL] [Abstract][Full Text] [Related]
5. Alcohol, liver disease and the gut microbiota. Bajaj JS Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227 [TBL] [Abstract][Full Text] [Related]
6. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318 [TBL] [Abstract][Full Text] [Related]
7. The gut-liver axis in liver disease: Pathophysiological basis for therapy. Albillos A; de Gottardi A; Rescigno M J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696 [TBL] [Abstract][Full Text] [Related]
8. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Arab JP; Martin-Mateos RM; Shah VH Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391 [TBL] [Abstract][Full Text] [Related]
9. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417 [TBL] [Abstract][Full Text] [Related]
10. [Gut microbiota and nonalcoholic steatohepatitis]. Kessoku T; Imajo K; Kobayashi T; Honda Y; Ogawa Y; Yoneda M; Saito S; Nakajima A Nihon Yakurigaku Zasshi; 2018; 152(4):187-193. PubMed ID: 30298840 [TBL] [Abstract][Full Text] [Related]
11. Altered profile of human gut microbiome is associated with cirrhosis and its complications. Bajaj JS; Heuman DM; Hylemon PB; Sanyal AJ; White MB; Monteith P; Noble NA; Unser AB; Daita K; Fisher AR; Sikaroodi M; Gillevet PM J Hepatol; 2014 May; 60(5):940-7. PubMed ID: 24374295 [TBL] [Abstract][Full Text] [Related]
13. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642 [TBL] [Abstract][Full Text] [Related]
14. Gut microbiota and host metabolism in liver cirrhosis. Usami M; Miyoshi M; Yamashita H World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989 [TBL] [Abstract][Full Text] [Related]
15. Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis. Qamar AA J Clin Gastroenterol; 2015; 49 Suppl 1():S28-32. PubMed ID: 26447961 [TBL] [Abstract][Full Text] [Related]
16. Potential mechanisms linking gut microbiota and portal hypertension. Baffy G Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513 [TBL] [Abstract][Full Text] [Related]
17. Clinical impact of microbiome in patients with decompensated cirrhosis. Oikonomou T; Papatheodoridis GV; Samarkos M; Goulis I; Cholongitas E World J Gastroenterol; 2018 Sep; 24(34):3813-3820. PubMed ID: 30228776 [TBL] [Abstract][Full Text] [Related]
18. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. Ghoshal UC; Goel A; Quigley EMM Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578 [TBL] [Abstract][Full Text] [Related]
19. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Sharpton SR; Ajmera V; Loomba R Clin Gastroenterol Hepatol; 2019 Jan; 17(2):296-306. PubMed ID: 30196156 [TBL] [Abstract][Full Text] [Related]
20. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. van Best N; Jansen PL; Rensen SS Hepatol Int; 2015 Jul; 9(3):406-15. PubMed ID: 26067771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]